Hyperpigmentation Disorder Treatment Market Size was valued at USD 6.98 Bn in 2023 and is predicted to reach USD 12.54 Bn by 2031 at a 7.8% CAGR during the forecast period for 2024-2031.
Hyperpigmentation disorder treatment issues can be treated with a combination of medical treatments and cosmetic operations that attempt to lessen the appearance and severity of hyperpigmented skin. The rising number of cases of hyperpigmentation disorder treatment, the need for novel treatments, and the development of more effective lasers are all factors that should lead to expansion in the hyperpigmentation disorder treatment market. In addition, the market is growing because people are becoming more aware of pigmentation problems, which is driving up the demand for safe and effective treatments. In addition, the projection period for the hyperpigmentation disorder treatment market is anticipated to be filled with attractive potential driven by the increased demand for outpatient and microsurgical procedures.
However, the market growth is hampered by the absence of knowledge requirements for the safety and health of hyperpigmentation disorder treatment, stringent regulatory standards, and the high cost of hyperpigmentation disorder treatment. Companies in the global hyperpigmentation disorder treatment market are finding profitable prospects due to technological improvements in cosmeceuticals and the accompanying increase in skincare products using cosmeceuticals. So that they can increase their market share, major companies are pouring money into nanotechnology research and development. Furthermore, an increasing number of individuals are seeking professional treatment for hyperpigmentation as a result of better access to healthcare, particularly in emerging nations.
Competitive Landscape
Some of the Major Key Players in the Hyperpigmentation Disorder Treatment Market are
- AbbVie Inc
- Bayer AG
- Epipharm AG
- Galderma Laboratories
- Obagi Cosmeceuticals LLC
- Lutronic Corporation
- La Pristine
- L’oreal S.A
- Pierre Fabre Group
- Vivier Pharma USA
- Other Prominent Players
Market Segmentation:
The hyperpigmentation disorder treatment market is segmented based on treatment type, condition, and end user. Based on treatment type, the market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. By condition, the market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. By end user, the market is segmented into hospitals, dermatology centers, and others.
Laser Therapy Segment is Accounted as a Major Contributor to the Hyperpigmentation Disorder Treatment Market
Laser therapy is expected to hold a major global market share in 2023 because it is generally considered to be an excellent strategy for decreasing hyperpigmentation. Due to ever-improving laser technology, these treatments are now safer, more effective, and can be used on a broader variety of skin types. Laser therapy for hyperpigmentation disorder treatment has also seen increased uptake from both patients and doctors as word of its efficacy spreads.
Dermatology Segment to Witness Growth at a Rapid Rate
The dermatology segment is growing in the hyperpigmentation disorder treatment market because dermatologists best manage hyperpigmentation disorders due to their extensive training concerning the examination and care of skin disorders. Dermatologists are seeing an increase in patients as more people learn about the need for skin health and the benefits of early treatment for hyperpigmentation. Hyperpigmentation disorder concerns are becoming more common, which is leading to a desire for dermatological care that is specialized.
In the Region, the North American Hyperpigmentation Disorder Treatment Market Holds a Significant Revenue Share
The North American hyperpigmentation disorder treatment market is expected to register the highest market share in revenue in the near future. It can be attributed to the highly developed healthcare system, remarkable dermatological technology, a robust healthcare system, and a high level of public understanding regarding skin care and aesthetic procedures. In addition, Asia Pacific is projected to grow rapidly in the global hyperpigmentation disorder treatment market due to the fact that, as the population grows, more individuals will require healthcare access. The incidence of age-related hyperpigmentation is on the rise because of the growing elderly population in the region.
Recent Developments:
- In January 2024, BlueRock Therapeutics LP, a fully-owned, independently run subsidiary of Bayer AG, announced a partnership with Rune Labs and Emerald Innovations to enhance wearable and invisible contactless digital health technology monitoring and data collection for Parkinson’s disease clinical trials.
- In April 2024, AbbVie is investing almost €150 million in its second-largest R&D center worldwide, a new central research building called “LUnA,” and has broken ground on it. More than 300 researchers and scientists will call a brand new, state-of-the-art research and laboratory building on the main campus home.
Hyperpigmentation Disorder Treatment Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 6.98 Bn |
|
Revenue Forecast In 2031 |
USD 12.54 Bn |
|
Growth Rate CAGR |
CAGR of 7.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment Type, By Condition, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
AbbVie Inc, Bayer AG, Epipharm AG, Galderma Laboratories, Obagi Cosmeceuticals LLC, Lutronic Corporation, La Pristine, L’oreal S.A, Pierre Fabre Group, and Vivier Pharma USA. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
